超越传统：晚期非小细胞肺癌靶向治疗的新视野
Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer.
作者信息
Tartarone Alfredo, Lapadula Vittoria, Di Micco Concetta, Rossi Gemma, Ottanelli Carlotta, Marini Andrea, Giorgione Roberta, Ferrari Katia, Catalano Martina, Voltolini Luca, Mini Enrico, Roviello Giandomenico
机构信息
Department of Onco-Hematology, Division of Medical Oncology IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
出版信息
Front Oncol. 2021 May 21;11:632256. doi: 10.3389/fonc.2021.632256. eCollection 2021.
In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
在过去几年中，针对致癌驱动因子的靶向治疗的出现显著提高了具有良好毒性特征的非小细胞肺癌（NSCLC）患者的生存率。因此，对于所有被诊断为晚期疾病的NSCLC患者（尤其是腺癌患者），都应进行基因检测，至少包括EGFR突变和ALK/ROS1重排。本综述聚焦于新型可成药致癌驱动因子，如MET外显子14突变/MET扩增、RET融合、BRAF V600E突变、KRAS G12C突变、NTRK重排和HER2改变。
Zotero 插件